Adenoscan
Unemployment Takes Toll on the Heart »
"Nov. 19, 2012 -- Unemployment and a history of job loss may raise the risk for heart attack, a new study suggests.
The risk of heart attack may be highest during the first year of unemployment. And the more jobs a person loses, the hi"...
Adenoscan
Adenoscan Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Adenoscan (adenosine injection) is used in combination with thallium-201 for nuclear heart stress tests when the patient is unable to exercise adequately. Common side effects include flushing; chest discomfort; throat, neck or jaw discomfort; abdominal pain; lightheadness; nausea; headache; upset stomach; and pain at injection site. Serious events have occurred with Adenoscan, such as fatal cardiac arrest, life-threatening ventricular arrhythmias, and heart attack.
The recommended intravenous dose of Adenoscan for adults is 140 mcg/kg/min infused for six minutes (total dose of 0.84 mg/kg). Tell your doctor all medications you are taking. Avoid drinking large amounts of caffeine (such as in coffee, tea, or some soft drinks). No studies have been performed in pregnant women; Adenoscan should only be used during pregnancy if the benefits outweigh the risks. Discuss with your doctor the risks of breastfeeding and use of Adenoscan.
Our Adenoscan (adenosine) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Adenoscan FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
The following reactions with an incidence of at least 1% were reported with intravenous Adenoscan (adenosine injection) among 1421 patients enrolled in controlled and uncontrolled U.S. clinical trials. Despite the short half-life of adenosine, 10.6% of the side effects occurred not with the infusion of Adenoscan (adenosine injection) but several hours after the infusion terminated. Also, 8.4% of the side effects that began coincident with the infusion persisted for up to 24 hours after the infusion was complete. In many cases, it is not possible to know whether these late adverse events are the result of Adenoscan (adenosine injection) infusion.
| Flushing | 44% |
| Chest discomfort | 40% |
| Dyspnea or urge to breathe deeply | 28% |
| Headache | 18% |
| Throat, neck or jaw discomfort | 15% |
| Gastrointestinal discomfort | 13% |
| Lightheadedness/dizziness | 12% |
| Upper extremity discomfort | 4% |
| ST segment depression | 3% |
| First-degree AV block | 3% |
| Second-degree AV block | 3% |
| Paresthesia | 2% |
| Hypotension | 2% |
| Nervousness | 2% |
| Arrhythmias | 1% |
Adverse experiences of any severity reported in less than 1% of patients include:
Body as a Whole
Back discomfort; lower extremity discomfort; weakness
Cardiovascular System
Nonfatal myocardial infarction; life-threatening ventricular arrhythmia; third-degree AV block; bradycardia; palpitation; sinus exit block; sinus pause; sweating; T-wave changes; hypertension (systolic blood pressure > 200 mm Hg)
Central Nervous System
Drowsiness; emotional instability; tremors
Genital/Urinary System
Vaginal pressure; urgency
Respiratory System
Cough
Special Senses
Blurred vision; dry mouth; ear discomfort; metallic taste; nasal congestion; scotomas; tongue discomfort
Post Marketing Experience (see WARNINGS)
The following adverse events have been reported from marketing experience with Adenoscan (adenosine injection) . Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, (3) strength of causal connection to the drug, or a combination of these factors.
Body as a Whole
Injection site reaction
Central Nervous System
Seizure activity, including tonic clonic (grand mal) seizures, and loss of consciousness
Digestive
Nausea and vomiting
Respiratory
Respiratory arrest, throat tightness
Read the entire FDA prescribing information for Adenoscan (Adenosine Injection) »
Additional Adenoscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Heart Health
Get the latest treatment options.
Updated & New
